Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT03689595
Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
Sponsor: Dana-Farber Cancer Institute
View on ClinicalTrials.gov
Summary
The PROMISE Study aims to establish a prospective cohort of individuals with precursor conditions to multiple myeloma, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). We will study these patients as a means to identify risk factors for progression to symptomatic multiple myeloma.
Key Details
Gender
All
Age Range
30 Years - Any
Study Type
OBSERVATIONAL
Enrollment
30000
Start Date
2018-10-31
Completion Date
2033-10-31
Last Updated
2025-11-26
Healthy Volunteers
Yes
Conditions
Interventions
OTHER
Sample of Blood
Collection of blood sample from participants
Locations (1)
Dana Farber Cancer Institute
Boston, Massachusetts, United States